A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: [177Lu]Lu-DOTA-TATE
DRUG: [68Ga]Ga-DOTA-TATE
OTHER: Temozolomide
OTHER: Radiotherapy

Sponsor

Novartis Pharmaceuticals